Pharmacogenomic study to predict warfarin stable dose in Japanese chidren.

Pharmacogenomic study to predict warfarin stable dose in Japanese chidren. - Pharmacogenomic study to predict warfarin stable dose in Japanese chidren.

Status

Unknown

Phases

Phase 3

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019397

Enrollment

480

Registered

2015-11-01

Start date

2015-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congenital heart disease, Kawasaki disease, myocardiac disease, thromboembolism

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children between 0 and 18 years of age at the time of study entry who treated with warfarin for the prevention or treatment of thromboembolism Patients who have already reached the optimal dose of warfarin and whose warfarin dose has not been changed within 28 days prior to DNA sample collection. Patients who have received a sufficient explanation for participation in the study and have obtained the written informed consent.

Exclusion criteria

Exclusion criteria: Patients whose warfarin dose has been changed within 28 days of the date of DNA sample collection Pregnant women and lactating women Patients who did not give written informed consent Patients who regularly (at least once/week) consume vitamin K-rich foods and supplements such as natto, chlorella, green juice, and St. John's wort (Hypericum perforatum) Patients who are judged by the attending physician to be inappropriate as subjects for this study

Design outcomes

Primary

Measure	Time frame
warfarin stable dose	—

Countries

Japan

Contacts

Public ContactTohru Kobayashi

National Center for Child Health and Development Department of Data Science

torukoba@nifty.com03-3416-0181

Outcome results